Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Investors with a lot of money to spend have taken a bearish stance on Merck & Co (NYSE:MRK).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRK, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Merck & Co.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $74,400, and 7, calls, for a total amount of $356,298.
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $117.0 for Merck & Co over the recent three months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Merck & Co's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Merck & Co's significant trades, within a strike price range of $100.0 to $117.0, over the past month.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
MRK | CALL | TRADE | BULLISH | 08/30/24 | $10.8 | $10.55 | $10.7 | $107.00 | $80.2K | 181 | 181 |
MRK | CALL | SWEEP | BEARISH | 10/18/24 | $4.6 | $4.5 | $4.55 | $115.00 | $75.9K | 1.6K | 167 |
MRK | PUT | TRADE | BEARISH | 09/20/24 | $0.14 | $0.05 | $0.12 | $100.00 | $74.4K | 7.4K | 6.2K |
MRK | CALL | SWEEP | BULLISH | 09/06/24 | $1.97 | $1.92 | $1.95 | $117.00 | $47.3K | 939 | 568 |
MRK | CALL | TRADE | BULLISH | 08/30/24 | $11.0 | $10.8 | $10.93 | $107.00 | $43.7K | 181 | 40 |
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
In the last month, 1 experts released ratings on this stock with an average target price of $155.0.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Merck & Co with Benzinga Pro for real-time alerts.
Posted In: MRK